Innoviva, Inc. (INVA) Stock
Key stats
- Market cap
- $1.34B
- Price / Earnings ratio
- 7.0x
- EPS (TTM)
- $2.72
- Volume
- Loading
- 52-week high
- $25.15
- 52-week low
- $18.70
Source: third-party data provider, as of November 13, 2026
Compare with INVA
Recent news

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
INVA

Do Options Traders Know Something About Innoviva Stock We Don't?
Do Options Traders Know Something About Innoviva Stock We Don't?
INVA

INVA vs. MRK: Which Stock Is the Better Value Option?
INVA vs. MRK: Which Stock Is the Better Value Option?
INVA

5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
INVA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 30.13
- MACD 12/26/9
- -0.48
- EMA 9 of MACD
- -0.23
- MACD histogram
- -0.25
- SMA 50
- $20.79
- Price below SMA 50
- EMA 50
- $20.71
- Price below EMA 50
- SMA 200
- $21.89
- Price below SMA 200
- EMA 200
- $21.38
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.29 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
INVA

Do Options Traders Know Something About Innoviva Stock We Don't?
Do Options Traders Know Something About Innoviva Stock We Don't?
INVA

INVA vs. MRK: Which Stock Is the Better Value Option?
INVA vs. MRK: Which Stock Is the Better Value Option?
INVA

5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
INVA

Innoviva to Participate in Upcoming Investor Conferences
Innoviva to Participate in Upcoming Investor Conferences
INVA

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
INVA

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
INVA

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
INVA

Supernus Pharmaceuticals Q2 Earnings Call Highlights
Supernus Pharmaceuticals Q2 Earnings Call Highlights
INVA

Nortiva Bio Launches to Develop Long-Acting Oral Medicines
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
INVA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Innoviva, Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Pavel Raifeld C.F.A. | CEO & Director | 1984 |
| Mr. Stephen Basso M.B.A. | Chief Financial Officer | 1966 |
| Ms. Marianne Zhen CPA | Chief Accounting Officer & Secretary | 1969 |
| Ms. Patricia M. Drake | Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc. | 1967 |
| Dr. David Altarac M.D., MPA | Chief Medical Officer of IST | 1962 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 30.13
- MACD 12/26/9
- -0.48
- EMA 9 of MACD
- -0.23
- MACD histogram
- -0.25
- SMA 50
- $20.79
- Price below SMA 50
- EMA 50
- $20.71
- Price below EMA 50
- SMA 200
- $21.89
- Price below SMA 200
- EMA 200
- $21.38
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $34.00
- Average
- $34.00
- High
- $34.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.3 | +3.9 | ||||||||||
| 2022 | -8.1 | +21.6 | +3.6 | -13.6 | -7.0 | +0.3 | -3.7 | -8.0 | -10.8 | +14.9 | -3.1 | +0.5 |
| 2023 | -4.7 | -5.3 | -1.1 | +3.0 | +15.4 | -2.9 | +6.8 | -4.6 | +1.3 | -4.3 | +11.5 | +14.7 |
| 2024 | -1.0 | -6.2 | +0.0 | -0.7 | +3.7 | +3.1 | +14.2 | +0.5 | -1.1 | +0.3 | -1.4 | -9.3 |
| 2025 | +7.1 | -2.7 | +1.9 | +4.2 | +4.9 | -0.2 | -8.2 | +9.7 | -12.6 | +0.2 | +20.0 | -5.5 |
| 2026 | +0.7 | +9.4 | +2.1 | -1.8 | -7.3 | +5.6 | -4.2 | +0.0 | +0.6 | +3.3 | -10.3 |




